Ernexa Therapeutics Inc. (ERNAW) Total liabilities 2016–2025
Ernexa Therapeutics Inc. (ERNAW) total liabilities at each fiscal year-end, per SEC filings.
$3.6MFY2025 · since FY2016: $12.6M → $3.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $3.6M | -92.4% |
| FY2024 | $46.9M | +361.1% |
| FY2023 | $10.2M | — |
| FY2021 | $5.2M | -41.9% |
| FY2020 | $9.0M | +13.7% |
| FY2019 | $7.9M | -28.0% |
| FY2018 | $11.0M | -12.6% |
| FY2017 | $12.6M | +0.5% |
| FY2016 | $12.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net incomeERNAW Net marginERNAW Gross profitERNAW Gross marginERNAW Operating incomeERNAW Operating marginERNAW Operating cash flowERNAW Free cash flowERNAW Capital expendituresERNAW Return on equityERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Shareholders’ equityERNAW overview →